@thecosmicwebb.bsky.social
..However, their impact might be eclipsed by yet another contender. Eli Lilly’s retatrutide — dubbed ‘triple G’ for its ability to target GLP-1, GIP and glucagon receptors — delivered an average weight reduction of 24% after 48 weeks, setting a new benchmark for obesity treatments.
Dozens of new obesity drugs are coming: these are the ones to watch
Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with fewer side effects.
www.nature.com
February 13, 2025 at 9:56 PM
..However, their impact might be eclipsed by yet another contender. Eli Lilly’s retatrutide — dubbed ‘triple G’ for its ability to target GLP-1, GIP and glucagon receptors — delivered an average weight reduction of 24% after 48 weeks, setting a new benchmark for obesity treatments.